Drug details
Trumenba (meningococcal group b vaccine)
type of Vaccines, Inactivated, Bacterial
Trumenba (Meningococcal Group B Vaccine) Suspension for intramuscular injection is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age.
This drug may have the following side effects:
- headache
- fever
- vomiting
- chills
- fatigue
- muscle pain
- joint pain
- diarrhea, or
- pain, redness, or swelling at the injection site
The following drugs are related to Trumenba, either as a replacement or used together:
- Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [meningococcal protein conjugate] and hepatitis b [recombinant] vaccine)
- Menactra (polysaccharide diphtheria toxoid conjugate vaccine)
- MenHibrix (meningococcal groups c and y and haemophilus b tetanus toxoid conjugate vaccine)
- Menveo (meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197)
- MenQuadfi (meningococcal (groups a, c, y, w) vaccine for injection)
- Menomune (meningococcal polysaccharide vaccine)